{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+of+physician%27s+choice&page=2", "query": { "intervention": "Treatment of physician's choice", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 157, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+of+physician%27s+choice&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+of+physician%27s+choice&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T16:38:55.234Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00039000", "title": "Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "HSPPC-96 or Oncophage", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2002-03", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2012-09-07", "last_synced_at": "2026-10-10T16:38:55.234Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039000" }, { "nct_id": "NCT02000622", "title": "Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer Metastatic", "BRCA 1 Gene Mutation", "BRCA 2 Gene Mutation" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Physician's choice chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 302, "start_date": "2014-03-27", "completion_date": "2025-12-23", "has_results": true, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-10T16:38:55.234Z", "location_count": 42, "location_summary": "San Diego, California • Santa Rosa, California • Whittier, California + 35 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02000622" }, { "nct_id": "NCT04527991", "title": "Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Metastatic Unresectable Urothelial Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Vinflunine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 711, "start_date": "2021-01-13", "completion_date": "2025-07-04", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-10T16:38:55.234Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04527991" }, { "nct_id": "NCT03149575", "title": "VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma Multiforme", "Glioblastoma", "Glioma", "GBM", "Brain Cancer" ], "interventions": [ { "name": "VAL-083, Dianhydrogalactitol", "type": "DRUG" }, { "name": "Physician's Choice of Salvage Therapy - temozolomide", "type": "DRUG" }, { "name": "Physician's Choice of Salvage Therapy - lomustine", "type": "DRUG" }, { "name": "Physician's Choice of Salvage Therapy - carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DelMar Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-10-27", "completion_date": "2019-08-31", "has_results": false, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-10-10T16:38:55.234Z", "location_count": 5, "location_summary": "Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Summit", "state": "New Jersey" }, { "city": "Amherst", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03149575" }, { "nct_id": "NCT06380751", "title": "Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "Saruparib (AZD5305)", "type": "DRUG" }, { "name": "Camizestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 788, "start_date": "2024-08-01", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-10T16:38:55.234Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06380751" }, { "nct_id": "NCT06829199", "title": "A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early Triple Negative Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Doxorubicin (hydrochloride)", "type": "DRUG" }, { "name": "Boserolimab", "type": "BIOLOGICAL" }, { "name": "Epirubicin Hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib (if approved/available locally)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-03-26", "completion_date": "2031-03-18", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-10-10T16:38:55.234Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06829199" }, { "nct_id": "NCT04059484", "title": "Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2019-10-22", "completion_date": "2025-01-02", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-10T16:38:55.234Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04059484" }, { "nct_id": "NCT06875128", "title": "Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer in the Liver" ], "interventions": [ { "name": "Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)", "type": "DRUG" }, { "name": "Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2026-01-29", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-10T16:38:55.234Z", "location_count": 4, "location_summary": "Tampa, Florida • Cleveland, Ohio • Columbus, Ohio + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06875128" }, { "nct_id": "NCT07173751", "title": "ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Nab-paclitaxel/Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 558, "start_date": "2025-10-30", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-10T16:38:55.234Z", "location_count": 71, "location_summary": "Springdale, Arkansas • La Jolla, California • Los Alamitos, California + 56 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07173751" }, { "nct_id": "NCT04562870", "title": "A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Physician's Choice Treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2021-03-17", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-10T16:38:55.234Z", "location_count": 4, "location_summary": "Pasadena, California • Aurora, Colorado • Niles, Illinois + 1 more", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Niles", "state": "Illinois" }, { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04562870" } ] }